Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients. - Wikidata - awgldk - TriplyDB

Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients.

Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients.

http://www.wikidata.org/entity/Q35956330

about

Variability in Cancer Risk and Outcomes Within US Latinos by National Origin and Genetic Ancestry Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer Lung cancer in Brazil: epidemiology and treatment challenges.Clinical and metabolic parameters in non-small cell lung carcinoma and colorectal cancer patients with and without KRAS mutations.EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).Epidermal growth factor receptor mutation frequency and non-small cell lung cancer management: implication for treatment choices.Cancer genes in lung cancer: racial disparities: are there any?Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist?Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia.Research status and funding trends of lung cancer biomarkers.EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer.Somatic mutation analysis of KRAS, BRAF, HER2 and PTEN in EGFR mutation-negative non-small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel deletion in HER2 gene from Indian patients.miRNAs as Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer: Current Perspectives.EGFR activating mutations and their association with response to platinum-doublet chemotherapy in Brazilian non-small cell lung cancer patients.

P2860

Q26740043-650843FE-A11A-4F20-94E7-004AAD05FDFE Q26781810-5C353F32-38DD-451F-B0BE-2F8ED903E9C3 Q30235908-9A332365-6FAD-43BA-807C-A74AFFFCC471 Q34347975-ADEEDF79-DF41-4F27-B36D-378129892AA1 Q36250691-1A87A2B9-0EA0-41FF-A908-F5FD192BFD0E Q36371275-CEC2CA8E-B798-4F5A-B216-1287CD6FFCFA Q36481954-9504DAC4-068E-422B-A00A-73A153DBBF45 Q37110396-36FD6905-60D1-492D-9186-2F4A78EF9846 Q37272817-387EE53F-CCA8-48B8-8171-F2EDA1E8C0FE Q37274578-AF126642-2165-421B-A74C-3CD0B3CD7140 Q38160089-B2A932A3-8BA2-43FA-A883-A70F2394AD49 Q51497614-E6A199FC-DB42-4A5D-983A-9A603EF89E39 Q53189857-C6C50DD1-D781-41DA-882A-34B823464708 Q54355354-12D18DDE-4D61-4C13-88C4-3099B983D745

P2860

Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients.

http://www.wikidata.org/entity/Q35956330

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients.

@ast

Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients.

@en

type

label

Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients.

@ast

Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients.

@en

prefLabel

Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients.

@ast

Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients.

@en

P1433

Q35956330-89D2A330-16A2-4D31-95AD-6854F9FE5D63

P1476

Q35956330-FF14D382-FD4C-4FDC-8DB9-1E6FA34948F7

P2093

Q35956330-3D2D1AFE-8B88-4470-8D49-6128502E1AE6

Q35956330-4499EAA6-72F4-4036-81B9-B1520E2BA251

Q35956330-633AE0CE-79B3-42DD-915B-69BC13A6E9FD

Q35956330-911715C3-A463-4C51-A7B9-33D78F3E3315

Q35956330-A3BB40F1-6410-437C-BDBB-5E01D49FFA0D

Q35956330-E205B2BC-A568-4C92-BDB6-180E37DCEA96

P2860

Q35956330-01E00E28-D044-41F9-AECB-C0E8A37F8E39

Q35956330-046C47E3-C6FE-4035-9B72-417A9ADB9A78

Q35956330-06C23312-A30C-4A54-A95F-0C2741FA2991

Q35956330-0B77C5BB-901C-4864-B235-C5A8AAE79577

Q35956330-18F55DF6-267C-45CA-9523-CA07536286AB

Q35956330-193FA54B-0326-40E9-B248-2F3FF1C3E5B0

Q35956330-1B67D1EA-E7C9-471F-86DC-A6AFD38E58E5

Q35956330-1C1693DF-688A-40FC-9412-C20374575837

Q35956330-3AC68A4B-9319-411F-8CDC-60FE198AD4C3

Q35956330-3D3158E0-A987-4A9A-84DE-CE700D1F85D8

P304

Q35956330-A7B56C2C-1903-4D1D-B9DC-D0997270BB73

P31

Q35956330-C6F0E818-9989-440D-8D8F-374FDC2D93B3

P356

Q35956330-EAA38FE9-064B-4002-846D-509317626F56

P433

Q35956330-FD526E57-91AC-4B65-906F-4023D179B76D

P478

Q35956330-3E723D2D-B5AF-4E3B-B729-31AFE0C25DD8

P577

Q35956330-07B952D6-09B3-41E6-941E-AAFC55B58952

P5875

Q35956330-2DA0848F-5755-41E9-BD1D-1509D1C89B7B

P698

Q35956330-5C4E4A23-C235-4CEB-B09A-D1E54BD14886

P932

Q35956330-4403654D-69C6-4A37-814D-7358B2E9B016

P356

P1433

P1476

Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients.

@en

P2093

Carlos E Bacchi

http://www.w3.org/2001/XMLSchema#string

Eduardo M Queiroga

http://www.w3.org/2001/XMLSchema#string

Elida B Ojopi

http://www.w3.org/2001/XMLSchema#string

Heloísa Ciol

http://www.w3.org/2001/XMLSchema#string

Luciana H Silva

http://www.w3.org/2001/XMLSchema#string

Lucimara C Benine

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Somatic mutations affect key pathways in lung adenocarcinoma

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features

Erlotinib in previously treated non-small-cell lung cancer

P304

419-424

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.6061/CLINICS/2012(05)03

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225185072

http://www.w3.org/2001/XMLSchema#string

P698

22666783

http://www.w3.org/2001/XMLSchema#string

P932

3351259

http://www.w3.org/2001/XMLSchema#string